エスケタミンは,治療に抵抗するうつ病に対する可能な補助療法である
Annie Huang1, Jennifer L Fernandez Vasquez1, Catherine A Yeager1
1From the DD Eisenhower Army Medical Center Family Medicine Residency, Augusta, GA (AH, JLFV, CAY).
Journal of the American Board of Family Medicine : JABFM
|February 20, 2026
まとめ
エスケタミンによる治療抵抗性うつ病の治療を補完すると,クエチアピンよりも高い寛解率を示します. エスケタミンは,治療が難しいうつ病の患者にとって,より効果的な選択肢を提供します.
科学分野:
- 精神科医は精神病を患っている.
- 薬理学 薬理学とは
背景:
- 治療抵抗性うつ病 (TRD) は,重要な臨床的課題となっています.
- TRDの現在の治療法は,有効性と副作用のプロファイルに制限があります.
研究 の 目的:
- 治療に抵抗するうつ病の患者におけるエスケタミン増強とケチアピン増強の有効性を比較する.
主な方法:
- TRD患者の寛解率を評価する比較研究.
- 患者は,既存の薬物療法の増強として,エスケタミンまたはケチアピンを投与しました.
主要な成果:
- エスケタミンによる増量投与は,ケチアピンと比較して,有意に高い寛解率を示した.
- これは,この患者集団におけるエスケタミンの優れた臨床結果を示唆しています.
結論:
- エスケトアミンの増強は,治療抵抗性うつ病の寛解を達成するためのクエチアピンよりも効果的な戦略です.
- これらの発見は,耐火性うつ病の患者にエスケタミンを考慮することを支持しています.
関連する概念動画
Electroconvulsive Therapy
1.4K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.4K
Antidepressant Drugs: MAOIs and Other Agents
991
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
991
Sedatives and Hypnotics Drugs: Miscellaneous Agents
674
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
674
Parenteral Anesthetics: Overview
789
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
789
Psychosis: Goals of Pharmacotherapy
620
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
620
Antiepileptic Drugs: Potassium Channel Activators
829
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
829


